

Patient Discussion Guide—First Visit

If you're noticing changes in your vision, such as blurriness, wavy lines, black or floating spots, or washed-out colors, you may be experiencing symptoms of certain retinal diseases. It may be DME, DR, Wet AMD, or MEfRVO. It's important to talk to your eye care team to learn more. Not sure exactly what to ask during your appointment? This guide can help.



Eyes and Vision:

- What does it mean if I'm experiencing blurriness, wavy lines, black or floating spots, and/or washed-out colors?
- How well do I see in each eye (what is my visual acuity)?
- What is low vision? Do I have it?
- What symptoms should I be concerned about?
- What tests will you do to check my eyes and my vision? How often will you do these tests?
- How can I monitor my vision for changes at home?
- Is there anything I should do to help protect my eyes?

Diagnosis/Management:

- What condition could be causing these symptoms?
- What is my diagnosis?
- What do I need to know about my condition?
- How will this disease progress over time?
- What are the long-term effects and possible complications of my condition?
- What can I do to help prevent it from getting worse?
- How can my condition be managed?
- Are there treatment options for my condition?
- Can you tell me about options and what I can expect?

Lifestyle:

- Where can I find resources related to my condition?
- Is there anything I can do to help improve my condition?
- How do I explain my condition to others?

Living With Low Vision:

- Do you have any resources or tips to help me live with low vision?
- How can I maintain my normal everyday activities?

Notes:

It's a good idea to be prepared before you arrive for your next appointment. Use this space to write down any symptoms you're experiencing, additional questions you may have, or notes you want to share with your eye care team.

INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

SELECT IMPORTANT SAFETY INFORMATION

EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

Please see additional Important Safety Information on next page and accompanying full Prescribing Information.

Explore www.EYLEA.us and the [EYLEA YouTube channel](#) to learn more about certain retinal diseases, symptoms, EYLEA as a treatment option, and resources available for support. Ask if EYLEA is right for you.

INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

IMPORTANT SAFETY INFORMATION

- EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
- Injections into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye) can occur. Inflammation in the eye has been reported with the use of EYLEA.
- In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
- There is a potential but rare risk of serious and sometimes fatal side effects, related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
- The most common side effects reported in patients receiving EYLEA were increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.
- You may experience temporary visual changes after an EYLEA injection and associated eye exams; do not drive or use machinery until your vision recovers sufficiently.
- Contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
- For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see accompanying full Prescribing Information, which is also available at EYLEA.com.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.

EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.

REGENERON

